---
document_datetime: 2025-12-02 05:22:59
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/rivastigmine-actavis.html
document_name: rivastigmine-actavis.html
version: success
processing_time: 0.1423431
conversion_datetime: 2025-12-27 15:44:20.982015
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Rivastigmine Actavis

[RSS](/en/individual-human-medicine.xml/65859)

##### Authorised

This medicine is authorised for use in the European Union

rivastigmine Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [Product information - with tracked changes](#product-information-with-tracked-changes-77238)
- [More information on Rivastigmine Actavis](#more-information-on-rivastigmine-actavis-1117)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Rivastigmine Actavis. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Rivastigmine Actavis.

Expand section

Collapse section

## What is Rivastigmine Actavis?

Rivastigmine Actavis is a medicine containing the active substance rivastigmine. It is available as capsules (1.5, 3, 4.5 and 6 mg).

Rivastigmine Actavis is a 'generic medicine'. This means that Rivastigmine Actavis is similar to a 'reference medicine' already authorised in the European Union (EU) called Exelon.

## What is Rivastigmine Actavis used for?

Rivastigmine Actavis is used for the treatment of patients with mild to moderately severe Alzheimer's dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour.

It can also be used to treat mild to moderately severe dementia in patients with Parkinson's disease.

The medicine can only be obtained with a prescription.

## How is Rivastigmine Actavis used?

Treatment with Rivastigmine Actavis should be initiated and supervised by a doctor who has experience in the diagnosis and treatment of Alzheimer's disease or dementia in patients with Parkinson's disease. Treatment should only be started if a caregiver is available who will regularly monitor the use of Rivastigmine Actavis by the patient. Treatment should continue as long as the medicine has a benefit, but the dose can be reduced or treatment interrupted if the patient has side effects.

Rivastigmine Actavis should be given twice a day, with morning and evening meals. The starting dose is 1.5 mg twice a day. In patients who tolerate this dose, it can be increased in 1.5 mg steps no more frequently than every two weeks, to a regular dose of 3 to 6 mg twice a day. The highest tolerated dose should be used to get the maximum benefit, but the dose should not exceed 6 mg twice a day.

## How does Rivastigmine Actavis work?

The active substance in Rivastigmine Actavis, rivastigmine, is a dementia medicine. In patients with Alzheimer's dementia or dementia due to Parkinson's disease, certain nerve cells die in the brain, resulting in low levels of the neurotransmitter acetylcholine (a chemical that allows nerve cells to communicate with each other). Rivastigmine works by blocking the enzymes that break down acetylcholine: acetylcholinesterase and butyrylcholinesterase. By blocking these enzymes, Rivastigmine Actavis allows levels of acetylcholine to increase in the brain, helping to reduce the symptoms of Alzheimer's dementia and dementia due to Parkinson's disease.

## How has Rivastigmine Actavis been studied?

Because Rivastigmine Actavis is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Exelon. Two medicines are bioequivalent when they produce the same levels of the active substance in the body.

## What are the benefits and risks of Rivastigmine Actavis?

Because Rivastigmine Actavis is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why has Rivastigmine Actavis been approved?

The CHMP concluded that, in accordance with EU requirements, Rivastigmine Actavis has been shown to have comparable quality and to be bioequivalent to Exelon. Therefore, the CHMP's view was that, as for Exelon, the benefit outweighs the identified risk. The Committee recommended that Rivastigmine Actavis be given marketing authorisation.

## Other information about Rivastigmine Actavis

The European Commission granted a marketing authorisation valid throughout the European Union for Rivastigmine Actavis on 16 June 2011.

For more information about treatment with Rivastigmine Actavis, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Rivastigmine Actavis : EPAR - Summary for the public

Reference Number: EMA/454217/2011

English (EN) (75.42 KB - PDF)

**First published:** 11/07/2011

**Last updated:** 13/07/2015

[View](/en/documents/overview/rivastigmine-actavis-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-900)

български (BG) (103.39 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/bg/documents/overview/rivastigmine-actavis-epar-summary-public_bg.pdf)

español (ES) (78.38 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/es/documents/overview/rivastigmine-actavis-epar-summary-public_es.pdf)

čeština (CS) (99.38 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/cs/documents/overview/rivastigmine-actavis-epar-summary-public_cs.pdf)

dansk (DA) (78.84 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/da/documents/overview/rivastigmine-actavis-epar-summary-public_da.pdf)

Deutsch (DE) (81.3 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/de/documents/overview/rivastigmine-actavis-epar-summary-public_de.pdf)

eesti keel (ET) (78.52 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/et/documents/overview/rivastigmine-actavis-epar-summary-public_et.pdf)

ελληνικά (EL) (103.39 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/el/documents/overview/rivastigmine-actavis-epar-summary-public_el.pdf)

français (FR) (81.14 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/fr/documents/overview/rivastigmine-actavis-epar-summary-public_fr.pdf)

hrvatski (HR) (85.77 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/hr/documents/overview/rivastigmine-actavis-epar-summary-public_hr.pdf)

italiano (IT) (79.13 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/it/documents/overview/rivastigmine-actavis-epar-summary-public_it.pdf)

latviešu valoda (LV) (96.01 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/lv/documents/overview/rivastigmine-actavis-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (96.36 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/lt/documents/overview/rivastigmine-actavis-epar-summary-public_lt.pdf)

magyar (HU) (94.98 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/hu/documents/overview/rivastigmine-actavis-epar-summary-public_hu.pdf)

Malti (MT) (99 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/mt/documents/overview/rivastigmine-actavis-epar-summary-public_mt.pdf)

Nederlands (NL) (81.04 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/nl/documents/overview/rivastigmine-actavis-epar-summary-public_nl.pdf)

polski (PL) (99.05 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/pl/documents/overview/rivastigmine-actavis-epar-summary-public_pl.pdf)

português (PT) (79.68 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/pt/documents/overview/rivastigmine-actavis-epar-summary-public_pt.pdf)

română (RO) (95.69 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/ro/documents/overview/rivastigmine-actavis-epar-summary-public_ro.pdf)

slovenčina (SK) (98.07 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/sk/documents/overview/rivastigmine-actavis-epar-summary-public_sk.pdf)

slovenščina (SL) (85.47 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/sl/documents/overview/rivastigmine-actavis-epar-summary-public_sl.pdf)

Suomi (FI) (78.58 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/fi/documents/overview/rivastigmine-actavis-epar-summary-public_fi.pdf)

svenska (SV) (79.3 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/sv/documents/overview/rivastigmine-actavis-epar-summary-public_sv.pdf)

## Product information

Rivastigmine Actavis : EPAR - Product Information

English (EN) (285.18 KB - PDF)

**First published:** 11/07/2011

**Last updated:** 13/06/2025

[View](/en/documents/product-information/rivastigmine-actavis-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-927)

български (BG) (406.6 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/06/2025

[View](/bg/documents/product-information/rivastigmine-actavis-epar-product-information_bg.pdf)

español (ES) (284.48 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/06/2025

[View](/es/documents/product-information/rivastigmine-actavis-epar-product-information_es.pdf)

čeština (CS) (382.42 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/06/2025

[View](/cs/documents/product-information/rivastigmine-actavis-epar-product-information_cs.pdf)

dansk (DA) (324.32 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/06/2025

[View](/da/documents/product-information/rivastigmine-actavis-epar-product-information_da.pdf)

Deutsch (DE) (318.19 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/06/2025

[View](/de/documents/product-information/rivastigmine-actavis-epar-product-information_de.pdf)

eesti keel (ET) (298.76 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/06/2025

[View](/et/documents/product-information/rivastigmine-actavis-epar-product-information_et.pdf)

ελληνικά (EL) (438.63 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/06/2025

[View](/el/documents/product-information/rivastigmine-actavis-epar-product-information_el.pdf)

français (FR) (309.82 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/06/2025

[View](/fr/documents/product-information/rivastigmine-actavis-epar-product-information_fr.pdf)

hrvatski (HR) (379.2 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/06/2025

[View](/hr/documents/product-information/rivastigmine-actavis-epar-product-information_hr.pdf)

íslenska (IS) (337.99 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/06/2025

[View](/is/documents/product-information/rivastigmine-actavis-epar-product-information_is.pdf)

italiano (IT) (303.44 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/06/2025

[View](/it/documents/product-information/rivastigmine-actavis-epar-product-information_it.pdf)

latviešu valoda (LV) (400.12 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/06/2025

[View](/lv/documents/product-information/rivastigmine-actavis-epar-product-information_lv.pdf)

lietuvių kalba (LT) (411.64 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/06/2025

[View](/lt/documents/product-information/rivastigmine-actavis-epar-product-information_lt.pdf)

magyar (HU) (453.69 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/06/2025

[View](/hu/documents/product-information/rivastigmine-actavis-epar-product-information_hu.pdf)

Malti (MT) (406.48 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/06/2025

[View](/mt/documents/product-information/rivastigmine-actavis-epar-product-information_mt.pdf)

Nederlands (NL) (295.63 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/06/2025

[View](/nl/documents/product-information/rivastigmine-actavis-epar-product-information_nl.pdf)

norsk (NO) (348.46 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/06/2025

[View](/no/documents/product-information/rivastigmine-actavis-epar-product-information_no.pdf)

polski (PL) (396.61 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/06/2025

[View](/pl/documents/product-information/rivastigmine-actavis-epar-product-information_pl.pdf)

português (PT) (312.87 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/06/2025

[View](/pt/documents/product-information/rivastigmine-actavis-epar-product-information_pt.pdf)

română (RO) (404.44 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/06/2025

[View](/ro/documents/product-information/rivastigmine-actavis-epar-product-information_ro.pdf)

slovenčina (SK) (401.5 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/06/2025

[View](/sk/documents/product-information/rivastigmine-actavis-epar-product-information_sk.pdf)

slovenščina (SL) (379.12 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/06/2025

[View](/sl/documents/product-information/rivastigmine-actavis-epar-product-information_sl.pdf)

Suomi (FI) (302.96 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/06/2025

[View](/fi/documents/product-information/rivastigmine-actavis-epar-product-information_fi.pdf)

svenska (SV) (316.61 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/06/2025

[View](/sv/documents/product-information/rivastigmine-actavis-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000278907 13/06/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Rivastigmine Actavis : EPAR - All Authorised presentations

English (EN) (23.34 KB - PDF)

**First published:** 11/07/2011

**Last updated:** 13/07/2015

[View](/en/documents/all-authorised-presentations/rivastigmine-actavis-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-408)

български (BG) (49.04 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/bg/documents/all-authorised-presentations/rivastigmine-actavis-epar-all-authorised-presentations_bg.pdf)

español (ES) (28.62 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/es/documents/all-authorised-presentations/rivastigmine-actavis-epar-all-authorised-presentations_es.pdf)

čeština (CS) (38.31 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/cs/documents/all-authorised-presentations/rivastigmine-actavis-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (24.06 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/da/documents/all-authorised-presentations/rivastigmine-actavis-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (29.81 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/de/documents/all-authorised-presentations/rivastigmine-actavis-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (27.2 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/et/documents/all-authorised-presentations/rivastigmine-actavis-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (43.89 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/el/documents/all-authorised-presentations/rivastigmine-actavis-epar-all-authorised-presentations_el.pdf)

français (FR) (19.87 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/fr/documents/all-authorised-presentations/rivastigmine-actavis-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (31.18 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/hr/documents/all-authorised-presentations/rivastigmine-actavis-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (26.67 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/is/documents/all-authorised-presentations/rivastigmine-actavis-epar-all-authorised-presentations_is.pdf)

italiano (IT) (25.76 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/it/documents/all-authorised-presentations/rivastigmine-actavis-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (43.02 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/lv/documents/all-authorised-presentations/rivastigmine-actavis-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (42.23 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/lt/documents/all-authorised-presentations/rivastigmine-actavis-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (40.81 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/hu/documents/all-authorised-presentations/rivastigmine-actavis-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (46.15 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/mt/documents/all-authorised-presentations/rivastigmine-actavis-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (23.16 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/nl/documents/all-authorised-presentations/rivastigmine-actavis-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (24.73 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/no/documents/all-authorised-presentations/rivastigmine-actavis-epar-all-authorised-presentations_no.pdf)

polski (PL) (45.1 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/pl/documents/all-authorised-presentations/rivastigmine-actavis-epar-all-authorised-presentations_pl.pdf)

português (PT) (23.8 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/pt/documents/all-authorised-presentations/rivastigmine-actavis-epar-all-authorised-presentations_pt.pdf)

română (RO) (40.59 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/ro/documents/all-authorised-presentations/rivastigmine-actavis-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (36.08 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/sk/documents/all-authorised-presentations/rivastigmine-actavis-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (38.84 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/sl/documents/all-authorised-presentations/rivastigmine-actavis-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (24.84 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/fi/documents/all-authorised-presentations/rivastigmine-actavis-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (23.87 KB - PDF)

**First published:**

11/07/2011

**Last updated:**

13/07/2015

[View](/sv/documents/all-authorised-presentations/rivastigmine-actavis-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Rivastigmine Actavis Active substance rivastigmine hydrogen tartrate International non-proprietary name (INN) or common name rivastigmine Therapeutic area (MeSH)

- Dementia
- Alzheimer Disease
- Parkinson Disease

Anatomical therapeutic chemical (ATC) code N06DA03

### Pharmacotherapeutic group

Psychoanaleptics

### Therapeutic indication

Symptomatic treatment of mild to moderately severe Alzheimer's dementia.

Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.

## Authorisation details

EMA product number EMEA/H/C/002036

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Actavis Group PTC ehf

Dalshraun 1

Marketing authorisation issued 16/06/2011 Revision 21

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Rivastigmine Actavis : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (273.47 KB - PDF)

**First published:** 19/03/2025

**Last updated:** 13/06/2025

[View](/en/documents/procedural-steps-after/rivastigmine-actavis-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Rivastigmine Actavis : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (205.25 KB - PDF)

**First published:** 12/01/2012

**Last updated:** 19/03/2025

[View](/en/documents/procedural-steps-after/rivastigmine-actavis-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Rivastigmine Actavis-H-C-2036-X-0005 : EPAR - Assessment Report - Extension

Adopted

Reference Number: EMA/CHMP/739928/2012

English (EN) (233.42 KB - PDF)

**First published:** 07/06/2013

**Last updated:** 07/06/2013

[View](/en/documents/variation-report/rivastigmine-actavis-h-c-2036-x-0005-epar-assessment-report-extension_en.pdf)

## Initial marketing authorisation documents

Rivastigmine Actavis : EPAR - Public assessment report

Adopted

Reference Number: EMA/454217/2011

English (EN) (294.7 KB - PDF)

**First published:** 11/07/2011

**Last updated:** 11/07/2011

[View](/en/documents/assessment-report/rivastigmine-actavis-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Rivastigmine Actavis

Adopted

Reference Number: EMA/98238/2011

English (EN) (47.76 KB - PDF)

**First published:** 15/04/2011

**Last updated:** 15/04/2011

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-rivastigmine-actavis_en.pdf)

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Rivastigmine Actavis : EPAR - Product information - tracked changes

English (EN) (158.81 KB - DOCX)

**First published:** 13/06/2025

[View](/en/documents/product-information-tracked-changes/rivastigmine-actavis-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-298)

български (BG) (180.47 KB - DOCX)

**First published:**

13/06/2025

[View](/bg/documents/product-information-tracked-changes/rivastigmine-actavis-epar-product-information-tracked-changes_bg.docx)

español (ES) (141.52 KB - DOCX)

**First published:**

13/06/2025

[View](/es/documents/product-information-tracked-changes/rivastigmine-actavis-epar-product-information-tracked-changes_es.docx)

čeština (CS) (136.77 KB - DOCX)

**First published:**

13/06/2025

[View](/cs/documents/product-information-tracked-changes/rivastigmine-actavis-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (157.42 KB - DOCX)

**First published:**

13/06/2025

[View](/da/documents/product-information-tracked-changes/rivastigmine-actavis-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (153.69 KB - DOCX)

**First published:**

13/06/2025

[View](/de/documents/product-information-tracked-changes/rivastigmine-actavis-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (138.12 KB - DOCX)

**First published:**

13/06/2025

[View](/et/documents/product-information-tracked-changes/rivastigmine-actavis-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (188.33 KB - DOCX)

**First published:**

13/06/2025

[View](/el/documents/product-information-tracked-changes/rivastigmine-actavis-epar-product-information-tracked-changes_el.docx)

français (FR) (173.29 KB - DOCX)

**First published:**

13/06/2025

[View](/fr/documents/product-information-tracked-changes/rivastigmine-actavis-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (146.58 KB - DOCX)

**First published:**

13/06/2025

[View](/hr/documents/product-information-tracked-changes/rivastigmine-actavis-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (203.63 KB - DOCX)

**First published:**

13/06/2025

[View](/is/documents/product-information-tracked-changes/rivastigmine-actavis-epar-product-information-tracked-changes_is.docx)

italiano (IT) (173.25 KB - DOCX)

**First published:**

13/06/2025

[View](/it/documents/product-information-tracked-changes/rivastigmine-actavis-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (168.85 KB - DOCX)

**First published:**

13/06/2025

[View](/lv/documents/product-information-tracked-changes/rivastigmine-actavis-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (162.37 KB - DOCX)

**First published:**

13/06/2025

[View](/lt/documents/product-information-tracked-changes/rivastigmine-actavis-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (155.52 KB - DOCX)

**First published:**

13/06/2025

[View](/hu/documents/product-information-tracked-changes/rivastigmine-actavis-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (144.39 KB - DOCX)

**First published:**

13/06/2025

[View](/mt/documents/product-information-tracked-changes/rivastigmine-actavis-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (148.69 KB - DOCX)

**First published:**

13/06/2025

[View](/nl/documents/product-information-tracked-changes/rivastigmine-actavis-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (164.46 KB - DOCX)

**First published:**

13/06/2025

[View](/no/documents/product-information-tracked-changes/rivastigmine-actavis-epar-product-information-tracked-changes_no.docx)

polski (PL) (144.43 KB - DOCX)

**First published:**

13/06/2025

[View](/pl/documents/product-information-tracked-changes/rivastigmine-actavis-epar-product-information-tracked-changes_pl.docx)

português (PT) (154.65 KB - DOCX)

**First published:**

13/06/2025

[View](/pt/documents/product-information-tracked-changes/rivastigmine-actavis-epar-product-information-tracked-changes_pt.docx)

română (RO) (131.66 KB - DOCX)

**First published:**

13/06/2025

[View](/ro/documents/product-information-tracked-changes/rivastigmine-actavis-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (147.35 KB - DOCX)

**First published:**

13/06/2025

[View](/sk/documents/product-information-tracked-changes/rivastigmine-actavis-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (150.63 KB - DOCX)

**First published:**

13/06/2025

[View](/sl/documents/product-information-tracked-changes/rivastigmine-actavis-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (152.04 KB - DOCX)

**First published:**

13/06/2025

[View](/fi/documents/product-information-tracked-changes/rivastigmine-actavis-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (138.59 KB - DOCX)

**First published:**

13/06/2025

[View](/sv/documents/product-information-tracked-changes/rivastigmine-actavis-epar-product-information-tracked-changes_sv.docx)

#### More information on Rivastigmine Actavis

Questions and answers on generic medicines

Reference Number: EMA/393905/2006 Rev. 2

English (EN) (66.45 KB - PDF)

**First published:** 09/07/2007

**Last updated:** 07/12/2012

[View](/en/documents/other/questions-and-answers-generic-medicines_en.pdf)

[Other languages (22)](#file-language-dropdown-211)

български (BG) (93.16 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/bg/documents/other/questions-and-answers-generic-medicines_bg.pdf)

español (ES) (68.3 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/es/documents/other/questions-and-answers-generic-medicines_es.pdf)

čeština (CS) (87.71 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/cs/documents/other/questions-and-answers-generic-medicines_cs.pdf)

dansk (DA) (66.79 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/da/documents/other/questions-and-answers-generic-medicines_da.pdf)

Deutsch (DE) (67.55 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/de/documents/other/questions-and-answers-generic-medicines_de.pdf)

eesti keel (ET) (65.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/et/documents/other/questions-and-answers-generic-medicines_et.pdf)

ελληνικά (EL) (91.29 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/el/documents/other/questions-and-answers-generic-medicines_el.pdf)

français (FR) (68.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fr/documents/other/questions-and-answers-generic-medicines_fr.pdf)

hrvatski (HR) (87.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hr/documents/other/questions-and-answers-generic-medicines_hr.pdf)

italiano (IT) (67.62 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/it/documents/other/questions-and-answers-generic-medicines_it.pdf)

latviešu valoda (LV) (111.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lv/documents/other/questions-and-answers-generic-medicines_lv.pdf)

lietuvių kalba (LT) (86.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/lt/documents/other/questions-and-answers-generic-medicines_lt.pdf)

magyar (HU) (85.76 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/hu/documents/other/questions-and-answers-generic-medicines_hu.pdf)

Malti (MT) (89.35 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/mt/documents/other/questions-and-answers-generic-medicines_mt.pdf)

Nederlands (NL) (66.81 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/nl/documents/other/questions-and-answers-generic-medicines_nl.pdf)

polski (PL) (88.51 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pl/documents/other/questions-and-answers-generic-medicines_pl.pdf)

português (PT) (68.32 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/pt/documents/other/questions-and-answers-generic-medicines_pt.pdf)

română (RO) (86.9 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/ro/documents/other/questions-and-answers-generic-medicines_ro.pdf)

slovenčina (SK) (87.73 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sk/documents/other/questions-and-answers-generic-medicines_sk.pdf)

slovenščina (SL) (84.8 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sl/documents/other/questions-and-answers-generic-medicines_sl.pdf)

Suomi (FI) (66.21 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/fi/documents/other/questions-and-answers-generic-medicines_fi.pdf)

svenska (SV) (67.11 KB - PDF)

**First published:**

09/07/2007

**Last updated:**

07/12/2012

[View](/sv/documents/other/questions-and-answers-generic-medicines_sv.pdf)

#### Topics

- [Generic and hybrid medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A54)
- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 13/06/2025

## Share this page

[Back to top](#main-content)